Verrica Pharmaceuticals Inc
NASDAQ:VRCA
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.9187
  • TODAY'S CHANGE (%)
    0.0888 (10.7001%)
  • Bid / Lots
    0.9114/ 3
  • Ask / Lots
    0.9200/ 22
  • Open / Previous Close
    0.8302 / 0.8299
  • Day Range
    0.8300
    0.9200
  • 52 Week Range
    0.7043
    11.4100
  • Volume
    767,818

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
VRCA
Verrica Pharmaceuticals Inc
35.4M
-0.5x
---
DARE
Dare Bioscience Inc
36.2M
-4.0x
---
NXGL
Nexgel Inc
21.9M
-6.1x
---
KALA
KALA BIO Inc
35.2M
-0.5x
---
BTAI
BioXcel Therapeutics Inc
27.7M
-0.2x
---
EVOK
Evoke Pharma Inc
4.2M
-0.3x
---
As of 2024-11-11

Company Information

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Contact Information

Headquarters
10 N High St Ste 200WEST CHESTER, PA, United States 19380-3014
Phone
484-453-3300
Fax
302-636-5454

Executives

Chairman of the Board
Paul Manning
President, Chief Executive Officer, Director
Jayson Rieger
Interim Chief Financial Officer, Interim Principal Financial Officer
John Kirby
General Counsel, Company Secretary, Chief Legal Office
Christopher Hayes
Chief Medical Officer
Gary Goldenberg

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$35.4M
Revenue (TTM)
$9.2M
Shares Outstanding
42.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.33
EPS
$-1.83
Book Value
$0.47
P/E Ratio
-0.5x
Price/Sales (TTM)
3.8
Price/Cash Flow (TTM)
---
Operating Margin
-843.05%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.